Human androgen deficiency: Insights gained from androgen receptor knockout mouse models

Asian Journal of Andrology

Volumn 16, Issue 2, 2014, Pages 169-177

  Rana, Kesha ^a   Davey, Rachel A ^a   Zajac, Jeffrey D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Androgen deficiency; Androgen receptor; Androgen receptor knockout mouse model

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR;

ADIPOSE TISSUE; ANDROGEN DEFICIENCY; BONE; BRAIN; CARDIOVASCULAR SYSTEM; GENETICALLY ENGINEERED MOUSE STRAIN; HEMATOPOIETIC SYSTEM; HORMONE ACTION; HUMAN; IMMUNE SYSTEM; KNOCKOUT MOUSE; MOUSE MODEL; MUSCLE; NONHUMAN; PHENOTYPE; PROSTATE; REVIEW;

ANDROGENS; ANIMALS; AUTOIMMUNE DISEASES; BONE MARROW DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; GLUCOSE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; MUSCLE, SKELETAL; OBESITY; OSTEOPOROSIS; PROSTATE; RECEPTORS, ANDROGEN;

EID: 84896790145     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.122590     Document Type: Review

References (103)

1. van Weerden WM, Bierings HG, van Steenbrugge GJ, de Jong FH, Schroder FH. Adrenal glands of mouse and rat do not synthesize androgens. Life Sci 1992; 50: 857-61.
2. MacLean HE, Warne GL, Zajac JD. Localization of functional domains in the androgen receptor. J Steroid Biochem Mol Biol 1997; 62: 233-42. (Pubitemid 27504754)
3. Estrada M, Espinosa A, Muller M, Jaimovich E. Testosterone stimulates intracellular calcium release and mitogen-activated protein kinases via a G protein-coupled receptor in skeletal muscle cells. Endocrinology 2003; 144: 3586-97. (Pubitemid 36904438)
4. Kang HY, Cho CL, Huang KL, Wang JC, Hu YC, et al. Nongenomic androgen activation of phosphatidylinositol 3-kinase/Akt signaling pathway in MC3T3-E1 osteoblasts. J Bone Miner Res 2004; 19: 1181-90.
5. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001; 104: 719-30. (Pubitemid 32241022)
6. Gill A, Jamnongjit M, Hammes SR. Androgens promote maturation and signaling in mouse oocytes independent of transcription: a release of inhibition model for mammalian oocyte meiosis. Mol Endocrinol 2004; 18: 97-104. (Pubitemid 38073157)
7. Kallio PJ, Poukka H, Moilanen A, Janne OA, Palvimo JJ. Androgen receptor-mediated transcriptional regulation in the absence of direct interaction with a specific DNA element. Mol Endocrinol 1995; 9: 1017-28.
8. Schneikert J, Peterziel H, Defossez PA, Klocker H, de Launoit Y, et al. Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J Biol Chem 1996; 271: 23907-13. (Pubitemid 26327365)
9. Webb CM, Adamson DL, de Zeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 1999; 83: 437-9. (Pubitemid 29066505)
10. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 2004; 64: 7156-68. (Pubitemid 39331031)
11. Haas D, White SN, Lutz LB, Rasar M, Hammes SR. The modulator of nongenomic actions of the estrogen receptor (MNAR) regulates transcription-independent androgen receptor-mediated signaling: evidence that MNAR participates in G protein-regulated meiosis in Xenopus laevis oocytes. Mol Endocrinol 2005; 19: 2035-46. (Pubitemid 41124199)
12. Jakacka M, Ito M, Martinson F, Ishikawa T, Lee EJ, et al. An estrogen receptor (ER) alpha deoxyribonucleic acid-binding domain knock-in mutation provides evidence for nonclassical ER pathway signaling in vivo. Mol Endocrinol 2002; 16: 2188-201. (Pubitemid 35155533)
13. Sato T, Matsumoto T, Kawano H, Watanabe T, Uematsu Y, et al. Brain masculinization requires androgen receptor function. Proc Natl Acad Sci USA 2004; 101: 1673-8. (Pubitemid 38234213)
14. Holdcraft RW, Braun RE. Androgen receptor function is required in Sertoli cells for the terminal differentiation of haploid spermatids. Development 2004; 131: 459-67. (Pubitemid 38181383)
15. Yeh S, Tsai MY, Xu Q, Mu XM, Lardy H, et al. Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci USA 2002; 99: 13498-503. (Pubitemid 35215410)
16. De Gendt K, Swinnen JV, Saunders PT, Schoonjans L, Dewerchin M, et al. A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci USA 2004; 101: 1327-32. (Pubitemid 38182688)
17. Notini AJ, Davey RA, McManus JF, Bate KL, Zajac JD. Genomic actions of the androgen receptor are required for normal male sexual differentiation in a mouse model. J Mol Endocrinol 2005; 35: 547-55. (Pubitemid 43025578)
18. Pang TP, Clarke MV, Ghasem-Zadeh A, Lee NK, Davey RA, et al. A physiological role for androgen actions in the absence of androgen receptor DNA binding activity. Mol Cell Endocrinol 2011; 348: 189-97.
19. Davey RA, MacLean HE. Current and future approaches using genetically modified mice in endocrine research. Am J Physiol Endocrinol Metab 2006; 291: E429-38. (Pubitemid 44352246)
20. De Gendt K, Verhoeven G. Tissue-.and cell-specific functions of the androgen receptor revealed through conditional knockout models in mice. Mol Cell Endocrinol 2012; 352: 13-25.
21. Davey RA, MacLean HE, McManus JF, Findlay DM, Zajac JD. Genetically modified animal models as tools for studying bone and mineral metabolism. J Bone Miner Res 2004; 19: 882-92. (Pubitemid 41103444)
22. MacLean HE, Chiu WM, Ma C, McManus JF, Davey RA, et al. A floxed allele of the androgen receptor gene causes hyperandrogenization in male mice. Physiol Genomics 2008; 33: 133-7. (Pubitemid 351451380)
23. Beamer WG, Donahue LR, Rosen CJ, Baylink DJ. Genetic variability in adult bone density among inbred strains of mice. Bone 1996; 18: 397-403. (Pubitemid 26152301)
24. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-22.
25. Ikeda Y, Aihara K, Sato T, Akaike M, Yoshizumi M, et al. Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem 2005; 280: 29661-6. (Pubitemid 41177042)
26. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84: 223-43. (Pubitemid 27398022)
27. Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg 1992; 216: 117-34.
28. Lai JJ, Lai KP, Zeng W, Chuang KH, Altuwaijri S, et al. Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: lessons from conditional AR knockout mice. Am J Pathol 2012; 181: 1504-12.
29. Huang CK, Tsai MY, Luo J, Kang HY, Lee SO, et al. Suppression of androgen receptor enhances the self-renewal of mesenchymal stem cells through elevated expression of EGFR. Biochim Biophys Acta 2013; 1833: 1222-34.
30. Ashcroft GS, Mills SJ. Androgen receptor-mediated inhibition of cutaneous wound healing. J Clin Invest 2002; 110: 615-24. (Pubitemid 34988785)
31. Lai JJ, Lai KP, Chuang KH, Chang P, Yu IC, et al. Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J Clin Invest 2009; 119: 3739-51.
32. Eaton VS, Blackmore TK. Nilutamide-induced neutropenia. BJU Int 2001; 88: 801-2.
33. Lai KP, Lai JJ, Chang P, Altuwaijri S, Hsu JW, et al. Targeting thymic epithelia AR enhances T-cell reconstitution and bone marrow transplant grafting efficacy. Mol Endocrinol 2013; 27: 25-37.
34. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, et al. Androgens and bone. Endocr Rev 2004; 25: 389-425. (Pubitemid 38786452)
35. Basaria S, Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. Am J Med 2001; 110: 563-72.
36. Wiren KM. Androgens and bone growth: it's location, location, location. Curr Opin Pharmacol 2005; 5: 626-32. (Pubitemid 41614463)
37. Bertelloni S, Baroncelli GI, Ferdeghini M, Perri G, Saggese G. Normal volumetric bone mineral density and bone turnover in young men with histories of constitutional delay of puberty. J Clin Endocrinol Metab 1998; 83: 4280-3. (Pubitemid 29100122)
38. MacLean HE, Moore AJ, Sastra SA, Morris HA, Ghasem-Zadeh A, et al. DNA-binding-dependent androgen receptor signaling contributes to gender differences and has physiological actions in males and females. J Endocrinol 2010; 206: 93-103.
39. Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, et al. Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA 2003; 100: 9416-21. (Pubitemid 37033943)
40. Venken K, De Gendt K, Boonen S, Ophoff J, Bouillon R, et al. Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model. J Bone Miner Res 2006; 21: 576-85.
41. Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahn DB, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA 1989; 86: 854-7. (Pubitemid 19056254)
42. Kasperk CH, Wergedal JE, Farley JR, Linkhart TA, Turner RT, et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989; 124: 1576-8. (Pubitemid 19082736)
43. Wiren KM, Zhang XW, Toombs AR, Kasparcova V, Gentile MA, et al. Targeted overexpression of androgen receptor in osteoblasts: uxpected complex bone phenotype in growing animals. Endocrinology 2004; 145: 3507-22. (Pubitemid 38830023)
44. Wiren KM, Semirale AA, Zhang XW, Woo A, Tommasini SM, et al. Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis: a model for compartment-specific androgen action in the skeleton. Bone 2008; 43: 440-51.
45. Liu F, Woitge HW, Braut A, Kronenberg MS, Lichtler AC, et al. Expression and activity of osteoblast-targeted Cre recombinase transgenes in murine skeletal tissues. Int J Dev Biol 2004; 48: 645-53. (Pubitemid 39506707)
46. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 2002; 277: 44005-12. (Pubitemid 36157826)
47. Notini AJ, McManus JF, Moore A, Bouxsein M, Jimenez M, et al. Osteoblast deletion of exon 3 of the androgen receptor gene results in trabecular bone loss in adult male mice. J Bone Miner Res 2007; 22: 347-56. (Pubitemid 46797117)
48. Chiang C, Chiu M, Moore AJ, Anderson PH, Ghasem-Zadeh A, et al. Mineralization and bone resorption are regulated by the androgen receptor in male mice. J Bone Miner Res 2008; 24: 621-31.
49. Sinnesael M, Claessens F, Laurent M, Dubois V, Boonen S, et al. Androgen receptor (AR) in osteocytes is important for the maintenance of male skeletal integrity: evidence from targeted AR disruption in mouse osteocytes. J Bone Miner Res 2012; 27: 2535-43.
50. Russell PK, Clarke MV, Skinner JP, Pang TP, Zajac JD, et al. Identification of gene pathways altered by deletion of the androgen receptor specifically in mineralizing osteoblasts and osteocytes in mice. J Mol Endocrinol 2012; 49: 1-10.
51. Tobias JH, Chambers TJ. The effect of sex hormones on bone resorption by rat osteoclasts. Acta Endocrinol 1991; 124: 121-7.
52. Caputo CB, Meadows D, Raisz LG. Failure of estrogens and androgens to inhibit bone resorption in tissue culture. Endocrinology 1976; 98: 1065-8.
53. Pederson L, Kremer M, Judd J, Pascoe D, Spelsberg TC, et al. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci USA 1999; 96: 505-10. (Pubitemid 29061238)
54. Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM, et al. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 2001; 142: 3800-8. (Pubitemid 32802650)
55. Chen Q, Kaji H, Sugimoto T, Chihara K. Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor. FEBS Lett 2001; 491: 91-3. (Pubitemid 32172008)
56. Baran DT, Bergfeld MA, Teitelbaum SL, Avioli LV. Effect of testosterone therapy on bone formation in an osteoporotic hypogonadal male. Calcif Tissue Res 1978; 26: 103-6.
57. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000; 74: 311-7. (Pubitemid 32126243)
58. Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, et al. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 2003; 111: 1651-64. (Pubitemid 38057747)
59. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670-7. (Pubitemid 32269134)
60. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2839-53. (Pubitemid 32269162)
61. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1-7. (Pubitemid 26230806)
62. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647-53. (Pubitemid 30641987)
63. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281: E1172-81.
64. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab 2002; 283: E154-64. (Pubitemid 34686681)
65. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639-50.
66. Mauras N, Hayes V, Welch S, Rini A, Helgeson K, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998; 83: 1886-92. (Pubitemid 28496311)
67. Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol 2002; 56: 779-86. (Pubitemid 34785910)
68. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol 2011; 74: 377-83.
69. MacLean HE, Chiu WS, Notini AJ, Axell AM, Davey RA, et al. Impaired skeletal muscle development and function in male, but not female, genomic androgen receptor knockout mice. Faseb J 2008; 22: 2676-89.
70. Altuwaijri S, Lee DK, Chuang KH, Ting HJ, Yang Z, et al. Androgen receptor regulates expression of skeletal muscle-specific proteins and muscle cell types. Endocrine 2004; 25: 27-32. (Pubitemid 41264535)
71. Ophoff J, Callewaert F, Venken K, De Gendt K, Ohlsson C, et al. Physical activity in the androgen receptor knockout mouse: evidence for reversal of androgen deficiency on cancellous bone. Biochem Biophys Res Commun 2009; 378: 139-44.
72. Ophoff J, Van Proeyen K, Callewaert F, De Gendt K, De Bock K, et al. Androgen signaling in myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle strength or fatigue. Endocrinology 2009; 150: 3558-66.
73. Chambon C, Duteil D, Vignaud A, Ferry A, Messaddeq N, et al. Myocytic androgen receptor controls the strength but not the mass of limb muscles. Proc Natl Acad Sci USA 2010; 107: 14327-32.
74. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol 2006; 64: 355-65.
75. Grossmann M, Panagiotopolous S, Sharpe K, MacIsaac RJ, Clarke S, et al. Low testosterone and anaemia in men with type 2 diabetes. Clin Endocrinol 2009; 70: 547-53.
76. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008; 93: 1834-40. (Pubitemid 351656526)
77. Yeap BB, Chubb SA, Hyde Z, Jamrozik K, Hankey GJ, et al. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men Study. Eur J Endocrinol 2009; 161: 591-8.
78. Mah PM, Wittert GA. Obesity and testicular function. Mol Cell Endocrinol 2010; 316: 180-6.
79. Grossmann M, Gianatti EJ, Zajac JD. Testosterone and type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17: 247-56.
80. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906. (Pubitemid 43997730)
81. Gopal RA, Bothra N, Acharya SV, Ganesh HK, Bandgar TR, et al. Treatment of hypogonadism with testosterone in patients type 2 diabetes mellitus Endocr Pract. 2010; 16: 570-6.
82. Rana K, Fam BC, Clarke MV, Pang TP, Zajac JD, et al. Increased adiposity in DNA binding-dependent androgen receptor knockout male mice associated with decreased voluntary activity and not insulin resistance. Am J Physiol Endocrinol Metab 2011; 301: E767-78.
83. Lin HY, Xu Q, Yeh S, Wang RS, Sparks JD, et al. Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes 2005; 54: 1717-25. (Pubitemid 40770762)
84. Fan W, Yanase T, Nomura M, Okabe T, Goto K, et al. Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes 2005; 54: 1000-8. (Pubitemid 40450323)
85. Yu IC, Lin HY, Liu NC, Wang RS, Sparks JD, et al. Hyperleptinemia without obesity in male mice lacking androgen receptor in adipose tissue. Endocrinology 2008; 149: 2361-8. (Pubitemid 351574489)
86. McInnes KJ, Smith LB, Hunger NI, Saunders PT, Andrew R, et al. Deletion of the androgen receptor in adipose tissue in male mice elevates retinol binding protein 4 and reveals independent effects on visceral fat mass and on glucose homeostasis. Diabetes 2012; 61: 1072-81.
87. Yu IC, Lin HY, Liu NC, Sparks JD, Yeh S, et al. Neuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-kappaB-Mediated PTP1B expression. Diabetes 2013; 62: 411-23.
88. Grossmann M, Zajac JD. Management of side effects of androgen deprivation therapy. Endocrinol Metab Clin North Am 2011; 40: 655-71.
89. Simanainen U, Allan CM, Lim P, McPherson S, Jimenez M, et al. Disruption of prostate epithelial androgen receptor impedes prostate lobe-specific growth and function. Endocrinology 2007; 148: 2264-72. (Pubitemid 46997080)
90. Simanainen U, McNamara K, Gao YR, McPherson S, Desai R, et al. Anterior prostate epithelial AR inactivation modifies estrogen receptor expression and increases estrogen sensitivity. Am J Physiol Endocrinol Metab 2011; 301: E727-35.
91. Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, et al. Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci USA 2007; 104: 12679-84. (Pubitemid 47255214)
92. Welsh M, Moffat L, McNeilly A, Brownstein D, Saunders PT, et al. Smooth muscle cell-specific knockout of androgen receptor: a new model for prostatic disease. Endocrinology 2011; 152: 3541-51.
93. Yu S, Zhang C, Lin CC, Niu Y, Lai KP, et al. Altered prostate epithelial development and IGF-1 signal in mice lacking the androgen receptor in stromal smooth muscle cells. Prostate 2011; 71: 517-24.
94. Yu S, Yeh CR, Niu Y, Chang HC, Tsai YC, et al. Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts. Prostate 2012; 72: 437-49.
95. Lai KP, Yamashita S, Vitkus S, Shyr CR, Yeh S, et al. Suppressed prostate epithelial development with impaired branching morphogenesis in mice lacking stromal fibromuscular androgen receptor. Mol Endocrinol 2012; 26: 52-66.
96. Hull EM, Dominguez JM. Sexual behavior in male rodents. Horm Behav 2007; 52: 45-55. (Pubitemid 46809862)
97. Caplan PJ, Crawford M, Shibley Hyde J, Richardson JT. Gender differences in human cognition. New York: Oxford University Press; 1997. p. 3-182.
98. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci 1994; 108: 325-32. (Pubitemid 24142694)
99. Galea LAM, Kimura D. Sex differences in route-learning. Pers Individ Diff 1993; 14: 53-65.
100. O'Connor DB, Archer J, Hair WM, Wu FC. Activational effects of testosterone on cognitive function in men. Neuropsychologia 2001; 39: 1385-94. (Pubitemid 32918202)
101. Silverman I, Kastuk D, Choi J, Phillips K. Testosterone levels and spatial ability in men. Psychoneuroendocrinology 1999; 24: 813-22. (Pubitemid 29461054)
102. Iwahana E, Karatsoreos I, Shibata S, Silver R. Gonadectomy reveals sex differences in circadian rhythms and suprachiasmatic nucleus androgen receptors in mice. Horm Behav 2008; 53: 422-30.
103. Juntti SA, Tollkuhn J, Wu MV, Fraser EJ, Soderborg T, et al. The androgen receptor governs the execution, but not programming, of male sexual and territorial behaviors. Neuron 2010; 66: 260-72.